Immunity in vaginal candidiasis

Current Opinion in Infectious Diseases

Volumn 18, Issue 2, 2005, Pages 107-111

  Fidel Jr , Paul L ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Candida albicans; Innate immunity; Mucosal immunity; T cells; Vaginal candidiasis

Indexed keywords

CD4 ANTIGEN;

AGE DISTRIBUTION; ANTIBODY PRODUCTION; CELLULAR IMMUNITY; COHORT ANALYSIS; CORRELATION ANALYSIS; DISEASE MODEL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNITY; INFLAMMATION; LYMPHOCYTE COUNT; NEUTROPHIL; POLYMORPHONUCLEAR CELL; RECURRENT DISEASE; REVIEW; SYMPTOMATOLOGY; TH1 CELL; VAGINA CANDIDIASIS;

EID: 15044365399     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000160897.74492.a3     Document Type: Review

References (35)

1. Sobel JD. Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis 1992; 14:S148-S153.
2. Kent HL. Epidemiology of vaginitis. Am J Obstet Gynecol 1991; 165:1168-1175.
3. Lynch ME, Sobel JD, Fidel PL Jr. Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidasis. J Med Vet Mycol 1996; 34:337-339.
4. Romani L, Puccetti P, Bistoni F. Biological role of Th cell subsets in candidiasis. In: Romagnani S, editor. Th1 and Th2 cells in health and disease. Farmington, CT: Karger; 1996. pp. 114-137.
5. Fidel PL Jr, Sobel JD. Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin Micro Rev 1996; 9:335-348.
6. Fidel PL Jr, Sobel JD. Host defense against vaginal candidiasis. In: Calderone R, editor. Candida and candidiasis. Washington, DC: ASM Press; 2002. pp. 193-209.
7. Leigh JE, Barousse M, Swoboda RK, et al. Candida-specific systemic cell-mediated immune reactivities in HIV-infected persons with and without mucosal candidiaisis. J Infect Dis 2001; 183:277-285.
8. Schuman P, Sobel JD, Ohmit S, et al. Mucosal candidal colonization and candidiasis in women with or at risk for human immunodeficiency virus infection. Clin Infect Dis 1998; 27:1161-1167.
9. Fidel PL Jr, Sobel JD. Murine models of Candida vaginal infections. In: Zak O, Sande M, editors. Experimental models in antimicrobial chemotherapy. 2nd ed. London, UK: Academic Press; 1999. pp. 741-748.
10. Fidel PL Jr, Sobel JD. Protective immunity in experimental Candida vaginitis. Res Immunol 1998; 149:361-373.
11. Bernardis F, Boccanera M, Adriani D, et al. Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect Immun 1997; 65:3399-3405.
12. Santoni G, Boccanera M, Adriani D, et al. Immune cell-mediated protection against vaginal candidiasis: evidence for a major role of vaginal CD4(+) T cells and possible participation of other local lymphocyte effectors. Infect Immun 2002; 70:4791-4797.
13. Steele C, Ratterree M, Fidel PL Jr. Differential susceptibility to experimental vaginal candidiasis in macaques. J Infect Dis 1999; 180:802-810.
14. Wormley FL Jr, Steele C, Wozniak K, et al. Resistance of TCR δ-chain knockout mice to experimental Candida vaginitis. Infect Immun 2001; 69:7162-7164.
15. Fidel PL Jr, Wolf NA, KuKuruga MA. T lymphocytes in the murine vaginal mucosa are phenotypically distinct from those in the periphery. Infect Immun 1996; 64:3793-3799.
16. Taylor BN, Saavedra M, Fidel PL Jr. Local Th1/Th2 cytokine production during experimental vaginal candidiasis. Med Mycol 2000; 38:419-431.
17. Wormley FL Jr, Chaiban J, Fidel PL Jr. Cell adhesion molecule and lymphocyte activation marker expression during experimental vaginal candidiasis. Infect Immun 2001; 69:5072-5079.
18. Black CA, Eyers FM, Russell A, et al. Acute neutropenia decreases inflammation associated with murine vaginal candidiasis but has no effect on the course of infection. Infect Immun 1998; 66:1273-1275.
19. Fidel PL Jr, Luo W, Steele C, et al. Analysis of vaginal cell populations during experimental vaginal candidiasis. Infect Immun 1999; 67:3135-3140.
20. Little CH, Georgiou GM, Marceglia A, et al. Measurement of T-cell-derived antigen binding molecules and immunoglobulin G specific to Candida albicans mannan in sera of patients with recurrent vulvovaginal candidiasis. Infect Immun 2000; 68:3840-3847.
21. Steele C, Ozenci H, Luo W, et al. Growth inhibition of Candida albicans by vaginal cells from naive mice. Med Mycol 1999; 37:251-260.
22. Nomanbhoy F, Steele C, Yano J, Fidel PL Jr. Vaginal and oral epithelial cell anti-Candida activity. Infect Immun 2002; 70:7081-7088.
23. Barousse MM, Steele C, Dunlap K, et al. Growth inhibition of Candida albicans by human vaginal epithelial cells. J Infect Dis 2001; 184:1489-1493.
24. Wormley FL Jr, Outright JL, Fidel PL Jr. Multiple experimental designs to evaluate the role of T-cell-mediated immunity against experimental vaginal Candida albicans infection. Med Mycol 2003; 41:401-410. The report revealed the strongest evidence to date for the lack of any role for systemic or local T cells in host defense against vaginal candidiasis. Vaginitis in T-cell immunodeficient as well as knockout mice was similar to wild-type mice. Moreover, several approaches at mucosal and systemic immunization snowed no protection.
25. de Carvalho R, Cunha C, Silva D, et al. IgA, IgE, and IgG subclasses to Candida albicans in serum and vaginal fluid from patients with vulvovaginal candidiasis. Rev Assoc Med Bras 2003; 49:434-438.
26. Fidel PL Jr, Ginsburg KA, Cutright JL, et al. Vaginal-associated immunity in women with recurrent vulvovaginal candidiasis: evidence for vaginal Th1-type responses following intravaginal challenge with Candida antigen. J Infect Dis 1997; 176:728-739.
27. Mathur S, Virella G, Koistinen J, et al. Humoral immunity in vaginal candidiasis. Infect Immun 1977; 15:287-294.
28. Kirkpatrick CH, Rich RR, Bennett JE. Chronic mucocutaneous candidiasis: model building in cellular immunity. Ann Int Med 1971; 74:955-978.
29. Barousse M, Van Der Pol BJ, Fortenberry D, et al. Vaginal yeast colonization, prevalence of vaginitis, and associated local immunity in adolescents. Sex Trans Infect 2004; 80:48-53. This report revealed that adolescents can tolerate large numbers of vaginal yeast without a high incidence of symptomatic infection, suggestive of protective mechanisms against vaginitis.
30. Rylander E, Berglund A, Krassny C, Petrini B. Vulvovaginal Candida in a young sexually active population: prevalence and association with oro-genital sex and frequent pain at intercourse. Sex Trans Infect 2004; 80:54-57.
31. Fidel PL Jr, Barousse M, Espinosa T, et al. A live intravaginal Candida challenge in humans reveals new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. Infect Immun 2004; 72:2939-2946. This report revealed a possible paradigm shift for factors associated with susceptibility and resistance to vaginitis; symptomatic infection appears associated with a hyper response by neutrophils rather than a deficiency in adaptive immunity, whereas resistance to infection appears to be associated with a noninflammatory innate presence rather than an adaptive cell-mediated response.
32. Fidel PL Jr, Barousse M, Espinosa T, et al. Local immune responsiveness following intravaginal challenge with Candida antigen in adult women at different stages of the menstrual cycle. Med Mycol 2003; 41:97-109.
33. Hurd E, Domino S. Increased susceptibility of secretor factor gene Fut2-Null mice to experimental vaginal candidiasis. Infect Immun 2004; 72:4279-4281.
34. Clemons KV, Spearow JL, Parmar R, et al. Genetic susceptibility of mice to Candida albicans vaginitis correlates with host estrogen sensitivity. Infect Immun 2004; 72:4878-4880.
35. Chaim W, Foxman B, Sobel JD. Association of recurrent vaginal candidiasis and secretory ABO and Lewis phenotype. J Infect Dis 1997; 176:828-830.